Abstract
Background: Our previous studies showed that α-asaronol was a potential antiepileptic candidate. Here, twelve O-terminus modified ester derivatives of α-asaronol were designed, synthesized and evaluated their anticonvulsant activity.
Methods: All synthetic compounds were subjected to three animal models of seizure (MES, scPTZ and sc3-MP models) combined with neurotoxicity test, as well as the LDH inhibitory test. Furthermore, GABAA Receptor modulation and pharmacokinetic evaluation of compound 4k were also performed.
Results: Five compounds (4a, 4b, 4d, 4e and 4k) showed significant anticonvulsant properties at the dose of 30-300 mg/kg in MES and scPTZ test, but weak activity in sc3-MP model. Meanwhile, 4a, 4b, 4d and 4k showed good LDH inhibitory activity in vitro. Specifically, 4k was the best compound in above evaluation, and better than that of α-asaronol and reference compound (stiripentol). In addition, 4k could increase chloride ion influx by modulating GABAA receptor α1β2γ2 subtype with EC50 of 48.65 ± 10.31 μM and showed good PK profiles in rats with moderate oral bioavailability (51.5%).
Conclusion: These results suggested 4k possesses potential effectiveness in treatment of therapyresistant seizures and is expected to be developed as a novel molecule for safer and efficient anticonvulsants having neuroprotective effects as well as low toxicity.
Keywords: Drug design, α-asaronol ester derivatives, anticonvulsant, GABAA receptor α1β2γ2, LDH inhibitory, pharmacokinetics.
Graphical Abstract
[1]
Fisher, R.S. Redefining epilepsy. Curr. Opin. Neurol., 2015, 28(2), 130-135.
[http://dx.doi.org/10.1097/WCO.0000000000000174] [PMID: 25734953]
[http://dx.doi.org/10.1097/WCO.0000000000000174] [PMID: 25734953]
[3]
Perucca, E.; French, J.; Bialer, M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol., 2007, 6(9), 793-804.
[http://dx.doi.org/10.1016/S1474-4422(07)70215-6] [PMID: 17706563]
[http://dx.doi.org/10.1016/S1474-4422(07)70215-6] [PMID: 17706563]
[4]
Romero-Falcón, A.; de la Santa-Belda, E.; García-Contreras, R.; Varela, J.M. A case of valproate-associated hepatotoxicity treated with L-carnitine. Eur. J. Intern. Med., 2003, 14(5), 338-340.
[http://dx.doi.org/10.1016/S0953-6205(03)00104-3] [PMID: 13678762]
[http://dx.doi.org/10.1016/S0953-6205(03)00104-3] [PMID: 13678762]
[5]
Bosman, T.; Vonck, K.; Claeys, P.; Van Vlierberghe, H.; De Clercq, M.; De Reuck, J.; Boon, P. Enterocolitis: an adverse event in refractory epilepsy patients treated with levetiracetam? Seizure, 2004, 13(2), 76-81.
[http://dx.doi.org/10.1016/j.seizure.2003.09.010] [PMID: 15129834]
[http://dx.doi.org/10.1016/j.seizure.2003.09.010] [PMID: 15129834]
[6]
Ornoy, A. Neuroteratogens in man: an overview with special emphasis on the teratogenicity of antiepileptic drugs in pregnancy. Reprod. Toxicol., 2006, 22(2), 214-226.
[http://dx.doi.org/10.1016/j.reprotox.2006.03.014] [PMID: 16621443]
[http://dx.doi.org/10.1016/j.reprotox.2006.03.014] [PMID: 16621443]
[7]
He, X.; Bai, Y.; Zeng, M.; Zhao, Z.; Zhang, Q.; Xu, N.; Qin, F.; Wei, X.; Zhao, M.; Wu, N.; Li, Z.; Zhang, Y.; Fan, T-P.; Zheng, X. Anticonvulsant activities of α-asaronol ((E)-3′-hydroxyasarone), an active constituent derived from α-asarone. Pharmacol. Rep., 2018, 70(1), 69-74.
[http://dx.doi.org/10.1016/j.pharep.2017.08.004] [PMID: 29331789]
[http://dx.doi.org/10.1016/j.pharep.2017.08.004] [PMID: 29331789]
[8]
Jin, M.; Zhang, B.; Sun, Y.; Zhang, S.; Li, X.; Sik, A.; Bai, Y.; Zheng, X.; Liu, K. Involvement of peroxisome proliferator-activated receptor γ in anticonvulsant activity of α-asaronol against pentylenetetrazole-induced seizures in zebrafish. Neuropharmacology, 2020, 162, 107760-107760.
[http://dx.doi.org/10.1016/j.neuropharm.2019.107760] [PMID: 31493468]
[http://dx.doi.org/10.1016/j.neuropharm.2019.107760] [PMID: 31493468]
[9]
Sun, Y.; Bai, Y.; Zeng, M.; Chen, X.; Xie, J.; Li, B.; He, X.; Bai, Y.; Jia, P.; Meng, X.; Liang, J.; Wang, S.; Fan, T-P.; Wu, B.; Zheng, X. Pharmacokinetics and tissue distribution evaluation of α-asaronol and its main metabolite in rats by HPLC method. J. Pharm. Biomed. Anal., 2019, 172, 349-356.
[http://dx.doi.org/10.1016/j.jpba.2019.05.004] [PMID: 31085397]
[http://dx.doi.org/10.1016/j.jpba.2019.05.004] [PMID: 31085397]
[10]
Almeida, L.; Soares-da-Silva, P. Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics, 2007, 4(1), 88-96.
[http://dx.doi.org/10.1016/j.nurt.2006.10.005] [PMID: 17199020]
[http://dx.doi.org/10.1016/j.nurt.2006.10.005] [PMID: 17199020]
[11]
de Bono, J.S.; Logothetis, C.J.; Molina, A.; Fizazi, K.; North, S.; Chu, L.; Chi, K.N.; Jones, R.J.; Goodman, O.B., Jr; Saad, F.; Staffurth, J.N.; Mainwaring, P.; Harland, S.; Flaig, T.W.; Hutson, T.E.; Cheng, T.; Patterson, H.; Hainsworth, J.D.; Ryan, C.J.; Sternberg, C.N.; Ellard, S.L.; Fléchon, A.; Saleh, M.; Scholz, M.; Efstathiou, E.; Zivi, A.; Bianchini, D.; Loriot, Y.; Chieffo, N.; Kheoh, T.; Haqq, C.M.; Scher, H.I. COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med., 2011, 364(21), 1995-2005.
[http://dx.doi.org/10.1056/NEJMoa1014618] [PMID: 21612468]
[http://dx.doi.org/10.1056/NEJMoa1014618] [PMID: 21612468]
[12]
Jonckers, T.H.; Lin, T.I.; Buyck, C.; Lachau-Durand, S.; Vandyck, K.; Van Hoof, S.; Vandekerckhove, L.A.; Hu, L.; Berke, J.M.; Vijgen, L.; Dillen, L.L.; Cummings, M.D.; de Kock, H.; Nilsson, M.; Sund, C.; Rydegård, C.; Samuelsson, B.; Rosenquist, A.; Fanning, G.; Van Emelen, K.; Simmen, K.; Raboisson, P. 2′-Deoxy-2′-spirocyclopropylcytidine revisited: a new and selective inhibitor of the hepatitis C virus NS5B polymerase. J. Med. Chem., 2010, 53(22), 8150-8160.
[http://dx.doi.org/10.1021/jm101050a] [PMID: 21033671]
[http://dx.doi.org/10.1021/jm101050a] [PMID: 21033671]
[13]
Honda, T.; Kubo, S.; Masuda, T.; Arai, M.; Kobayashi, Y.; Yamashita, M. Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en. Bioorg. Med. Chem. Lett., 2009, 19(11), 2938-2940.
[http://dx.doi.org/10.1016/j.bmcl.2009.04.067] [PMID: 19414262]
[http://dx.doi.org/10.1016/j.bmcl.2009.04.067] [PMID: 19414262]
[14]
Balimane, P.; Sinko, P. Effect of ionization on the variable uptake of valacyclovir via the human intestinal peptide transporter (hPepT1) in CHO cells. Biopharm. Drug Dispos., 2000, 21(5), 165-174.
[http://dx.doi.org/10.1002/1099-081X(200007)21:5<165:AID-BDD225>3.0.CO;2-F] [PMID: 11180195]
[http://dx.doi.org/10.1002/1099-081X(200007)21:5<165:AID-BDD225>3.0.CO;2-F] [PMID: 11180195]
[15]
Shah, K.; Shrivastava, S.K.; Mishra, P. Synthesis, kinetics and pharmacological evaluation of mefenamic acid mutual prodrug. Acta Pol. Pharm., 2013, 70(5), 905-911.
[PMID: 24147370]
[PMID: 24147370]
[16]
Unverferth, K.; Engel, J.; Höfgen, N.; Rostock, A.; Günther, R.; Lankau, H-J.; Menzer, M.; Rolfs, A.; Liebscher, J.; Müller, B.; Hofmann, H.J. Synthesis, anticonvulsant activity, and structure-activity relationships of sodium channel blocking 3-aminopyrroles. J. Med. Chem., 1998, 41(1), 63-73.
[http://dx.doi.org/10.1021/jm970327j] [PMID: 9438023]
[http://dx.doi.org/10.1021/jm970327j] [PMID: 9438023]
[17]
Zheng, X.; Jia, P.; Bai, Y. Research strategy for Combination of Traditional Chinese Medicine Molecular Chemistry based on the traditional theory of “Jun-Chen-Zuo-Shi,”. J. Northwest Univ. Nat. Sci. Ed., 2015, 45, 405-412.
[18]
Sada, N.; Lee, S.; Katsu, T.; Otsuki, T.; Inoue, T. Epilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science, 2015, 347(6228), 1362-1367.
[http://dx.doi.org/10.1126/science.aaa1299] [PMID: 25792327]
[http://dx.doi.org/10.1126/science.aaa1299] [PMID: 25792327]
[19]
Scharfman, H.E. Neuroscience. Metabolic control of epilepsy. Science, 2015, 347(6228), 1312-1313.
[http://dx.doi.org/10.1126/science.aaa9607] [PMID: 25792315]
[http://dx.doi.org/10.1126/science.aaa9607] [PMID: 25792315]
[20]
Fisher, J.L. Interactions between modulators of the GABA(A) receptor: Stiripentol and benzodiazepines. Eur. J. Pharmacol., 2011, 654(2), 160-165.
[http://dx.doi.org/10.1016/j.ejphar.2010.12.037] [PMID: 21237147]
[http://dx.doi.org/10.1016/j.ejphar.2010.12.037] [PMID: 21237147]
[21]
McKernan, R.M.; Whiting, P.J. Which GABAA-receptor subtypes really occur in the brain? Trends Neurosci., 1996, 19(4), 139-143.
[http://dx.doi.org/10.1016/S0166-2236(96)80023-3] [PMID: 8658597]
[http://dx.doi.org/10.1016/S0166-2236(96)80023-3] [PMID: 8658597]
[22]
Lee, H.W.; Cho, C.S.; Kang, S.K.; Yoo, Y.S.; Shin, J.S.; Ahn, S.K. Design, synthesis, and antiangiogenic effects of a series of potent novel fumagillin analogues. Chem. Pharm. Bull. (Tokyo), 2007, 55(7), 1024-1029.
[http://dx.doi.org/10.1248/cpb.55.1024] [PMID: 17603194]
[http://dx.doi.org/10.1248/cpb.55.1024] [PMID: 17603194]
[23]
Krall, R.L.; Penry, J.K.; White, B.G.; Kupferberg, H.J.; Swinyard, E.A. Antiepileptic drug development: II. Anticonvulsant drug screening. Epilepsia, 1978, 19(4), 409-428.
[http://dx.doi.org/10.1111/j.1528-1157.1978.tb04507.x] [PMID: 699894]
[http://dx.doi.org/10.1111/j.1528-1157.1978.tb04507.x] [PMID: 699894]
[24]
Porter, R.J.; Cereghino, J.J.; Gladding, G.D.; Hessie, B.J.; Kupferberg, H.J.; Scoville, B.; White, B.G. Antiepileptic Drug Development Program. Cleve. Clin. Q., 1984, 51(2), 293-305.
[http://dx.doi.org/10.3949/ccjm.51.2.293] [PMID: 6380818]
[http://dx.doi.org/10.3949/ccjm.51.2.293] [PMID: 6380818]
[25]
Rapacz, A.; Obniska, J.; Wiklik-Poudel, B.; Rybka, S.; Sałat, K.; Filipek, B. Anticonvulsant and antinociceptive activity of new amides derived from 3-phenyl-2,5-dioxo-pyrrolidine-1-yl-acetic acid in mice. Eur. J. Pharmacol., 2016, 781, 239-249.
[http://dx.doi.org/10.1016/j.ejphar.2016.04.033] [PMID: 27089821]
[http://dx.doi.org/10.1016/j.ejphar.2016.04.033] [PMID: 27089821]
[26]
Granchi, C.; Roy, S.; Giacomelli, C.; Macchia, M.; Tuccinardi, T.; Martinelli, A.; Lanza, M.; Betti, L.; Giannaccini, G.; Lucacchini, A.; Funel, N.; León, L.G.; Giovannetti, E.; Peters, G.J.; Palchaudhuri, R.; Calvaresi, E.C.; Hergenrother, P.J.; Minutolo, F. Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. J. Med. Chem., 2011, 54(6), 1599-1612.
[http://dx.doi.org/10.1021/jm101007q] [PMID: 21332213]
[http://dx.doi.org/10.1021/jm101007q] [PMID: 21332213]
[27]
Madsen, C.; Jensen, A.A.; Liljefors, T.; Kristiansen, U.; Nielsen, B.; Hansen, C.P.; Larsen, M.; Ebert, B.; Bang-Andersen, B.; Krogsgaard-Larsen, P.; Frølund, B. 5-Substituted imidazole-4-acetic acid analogues: synthesis, modeling, and pharmacological characterization of a series of novel γ-aminobutyric acid(C) receptor agonists. J. Med. Chem., 2007, 50(17), 4147-4161.
[http://dx.doi.org/10.1021/jm070447j] [PMID: 17655213]
[http://dx.doi.org/10.1021/jm070447j] [PMID: 17655213]
[28]
Kim, T.; Mirafzal, G.A.; Liu, J.; Bauld, N.L. Is hole transfer involved in metalloporphyrin-catalyzed epoxidation? J. Am. Chem. Soc., 1993, 115, 7653-7664.
[http://dx.doi.org/10.1021/ja00070a009]
[http://dx.doi.org/10.1021/ja00070a009]
[29]
Duclos, R.I., Jr; Johnston, M.; Vadivel, S.K.; Makriyannis, A.; Glaser, S.T.; Gatley, S.J. A methodology for radiolabeling of the endocannabinoid 2-arachidonoylglycerol (2-AG). J. Org. Chem., 2011, 76(7), 2049-2055.
[http://dx.doi.org/10.1021/jo102277q] [PMID: 21370840]
[http://dx.doi.org/10.1021/jo102277q] [PMID: 21370840]
[30]
Tripathi, L.; Singh, R.; Stables, J.P. Design & synthesis of N′-[substituted] pyridine-4-carbohydrazides as potential anticonvulsant agents. Eur. J. Med. Chem., 2011, 46(2), 509-518.
[http://dx.doi.org/10.1016/j.ejmech.2010.11.030] [PMID: 21167624]
[http://dx.doi.org/10.1016/j.ejmech.2010.11.030] [PMID: 21167624]
[31]
Guo, L.J.; Wei, C.X.; Jia, J.H.; Zhao, L.M.; Quan, Z.S. Design and synthesis of 5-alkoxy-[1,2,4]triazolo[4,3-a]quinoline derivatives with anticonvulsant activity. Eur. J. Med. Chem., 2009, 44(3), 954-958.
[http://dx.doi.org/10.1016/j.ejmech.2008.07.010] [PMID: 18752871]
[http://dx.doi.org/10.1016/j.ejmech.2008.07.010] [PMID: 18752871]
[32]
Botros, S.; Khalil, N.A.; Naguib, B.H.; El-Dash, Y. Synthesis and anticonvulsant activity of new phenytoin derivatives. Eur. J. Med. Chem., 2013, 60, 57-63.
[http://dx.doi.org/10.1016/j.ejmech.2012.11.025] [PMID: 23287051]
[http://dx.doi.org/10.1016/j.ejmech.2012.11.025] [PMID: 23287051]
[33]
Löscher, W.; Nau, H. Pharmacological evaluation of various metabolites and analogues of valproic acid. Anticonvulsant and toxic potencies in mice. Neuropharmacology, 1985, 24(5), 427-435.
[http://dx.doi.org/10.1016/0028-3908(85)90028-0] [PMID: 3927183]
[http://dx.doi.org/10.1016/0028-3908(85)90028-0] [PMID: 3927183]
[35]
Poisson, M.; Huguet, F.; Savattier, A.; Bakri-Logeais, F.; Narcisse, G. A new type of anticonvulsant, stiripentol. Pharmacological profile and neurochemical study. Arzneimittelforschung, 1984, 34(2), 199-204.
[PMID: 6326778]
[PMID: 6326778]
[36]
Aboul-Enein, M.N.; El-Azzouny, A.A.; Attia, M.I.; Maklad, Y.A.; Amin, K.M.; Abdel-Rehim, M.; El-Behairy, M.F. Design and synthesis of novel stiripentol analogues as potential anticonvulsants. Eur. J. Med. Chem., 2012, 47(1), 360-369.
[http://dx.doi.org/10.1016/j.ejmech.2011.11.004] [PMID: 22118828]
[http://dx.doi.org/10.1016/j.ejmech.2011.11.004] [PMID: 22118828]
[37]
Ucar, H. Van derpoorten, K.; Cacciaguerra, S.; Spampinato, S.; Stables, J.P.; Depovere, P.; Isa, M.; Masereel, B.; Delarge, J.; Poupaert, J.H. Synthesis and anticonvulsant activity of 2(3H)-benzoxazolone and 2(3H)-benzothiazolone derivatives. J. Med. Chem., 1998, 41(7), 1138-1145.
[http://dx.doi.org/10.1021/jm970682+] [PMID: 9544213]
[http://dx.doi.org/10.1021/jm970682+] [PMID: 9544213]
Article Metrics
12
1